Cancer Research and Treatment

Hematologic malignancy

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts: Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(1):325-333. Published online April 22, 2022; DOI: https://doi.org/10.4143/crt.2022.008

Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
Cancer Cell International.2025;[Epub] CrossRef
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef
Recent advances in cellular immunotherapy for lymphoid malignancies
Haerim Chung, Hyunsoo Cho
Blood Research.2023; 58(4): 166. CrossRef
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
Biomedicine & Pharmacotherapy.2022; 153: 113341. CrossRef

8,124 View
367 Download
3 Web of Science
4 Crossref

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study: Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2022;54(4):1268-1277. Published online December 30, 2021; DOI: https://doi.org/10.4143/crt.2021.1168

Abstract PDF Supplementary Material PubReader ePub: Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.

8,169 View
304 Download
1 Web of Science

Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma: Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh, On behalf of the Consortium for Improving Survival of Lymphoma investigators; Cancer Res Treat. 2019;51(4):1302-1312. Published online February 14, 2019; DOI: https://doi.org/10.4143/crt.2018.555

Abstract PDF PubReader ePub

Purpose
Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.
Materials and Methods
We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.
Results
Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival.
Conclusion
PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.

Citations

Citations to this article as recorded by

Space-associated lymphomas: review of a heterogeneous group of old and new entities
Judith A Ferry
Diagnostic Histopathology.2024; 30(8): 430. CrossRef
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients
Julien Calvani, Laurence Gérard, Jehane Fadlallah, Elsa Poullot, Lionel Galicier, Cyrielle Robe, Margaux Garzaro, Remi Bertinchamp, David Boutboul, Wendy Cuccuini, Jean-Michel Cayuela, Philippe Gaulard, Éric Oksenhendler, Véronique Meignin
American Journal of Surgical Pathology.2022; 46(3): 353. CrossRef
A Rapidly Accumulating Effusion in an Immunocompetent Woman
Zein Kattih, Akhilesh Mahajan, Morana Vojnic, Jordan Steinberg, Alyssa Yurovitsky, Jin Ah Kim, Amory Novoselac
Chest.2022; 161(6): e377. CrossRef
Human herpesvirus‐8–positive primary effusion lymphoma in HIV‐negative patients: Single institution case series with a multidisciplinary characterization
Giovanni Rossi, Ilaria Cozzi, Irene Della Starza, Lucia Anna De Novi, Maria Stefania De Propris, Aurelia Gaeta, Luigi Petrucci, Alessandro Pulsoni, Federica Pulvirenti, Valeria Ascoli
Cancer Cytopathology.2021; 129(1): 62. CrossRef
Primary effusion lymphoma in human immune deficiency (HIV)‐negative non‐organ transplant immunocompetent patients
Lisi Yuan, James R. Cook, Tarik M. Elsheikh
Diagnostic Cytopathology.2020; 48(4): 380. CrossRef
Clinicopathologic characteristics and survival of patients with primary effusion lymphoma
Cristian Aguilar, Caddie Laberiano, Brady Beltran, Cecilia Diaz, Alvaro Taype-Rondan, Jorge J. Castillo
Leukemia & Lymphoma.2020; 61(9): 2093. CrossRef

7,008 View
159 Download
6 Web of Science
6 Crossref

Effect of Arsenic Trioxide in TRAIL (Tumor Necrosis Factor-related Apoptosis Inducing Ligand)-Mediated Apoptosis in Multiple Myeloma Cell Lines: Jae Ho Byun, Young Seon Hong, Hee Jeong Cheong, Sook Ja Kim, Nam Su Lee, Jong Ho Won, Dae Sik Hong, Hee Sook Park; Cancer Res Treat. 2003;35(6):472-477. Published online December 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.6.472

Abstract PDF: PURPOSE
The potential therapeutic application of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), in the treatment of multiple myeloma (MM), was recently proposed. However, there have been some problems with the use of TRAIL, due to the appearance of TRAIL-resistant cells in MM. The effect of arsenic trioxide (As2O3) on the rate of apoptosis induced by TRAIL was evaluated in MM cells.
MATERIALS AND METHODS
Using TRAIL-sensitive (RPMI- 8226) and TRAIL-resistant (ARH-77 and IM-9) MM cell lines, the cell viability, induction of apoptosis, and change in the caspases were examined after treatment with TRAIL alone, or in combination with various concentrations of As2O3.
RESULTS
Incubating the cell lines with As2O3 augmented the TRAIL-induced apoptosis in the MM cell lines, according to the As2O3 concentration. Apoptosis was mediated through caspase activation. When TRAIL was used alone, caspase8 was activated in the RPMI-8226 cell lines, but not in the ARH-77 and IM-9 cell lines. When As2O3 was added to TRAIL, caspase-9 was activated in the ARH-77 and IM-9 cells.
CONCLUSION
The use of As2O3, in combination with TRAIL, would help enhance the level of TRAIL-induced apoptosis, and overcome the TRAIL-resistance, in MM cells.

4,208 View
25 Download

High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Persistent/Relapsed Ovarian Cancer: So Eun Kim, Jong Ho Won, Hyun Soo Kim, Joon Sung Park, Chan Kyu Kim, Kyu Taeg Lee, Sung Kyu Park, Seung Ho Baick, Dae Sik Hong, Hee Sook Park, Hugh Chul Kim; Cancer Res Treat. 2002;34(6):439-443. Published online December 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.6.439

Abstract PDF

PURPOSE
High dose chemotherapy (HDC) is increasingly being used for ovarian cancer. Although early studies of autotransplantation for advanced ovarian cancer have been encouraging, most reported series were small, and no randomized trials have been reported. HDC and autologous hematopoietic stem cell transplantation were rarely performed in patients with ovarian cancer in Korea, and no results have been reported with the exception of one case report.
MATERIALS AND METHODS
We retrospectively analyzed 10 patients with refractory or relapsed ovarian cancer having received HDC and autologous peripheral blood stem cell transplantation (APBSCT), between January 1996 and September 1998, at the Soon Chun Hyang and Ajou University Hospitals.
RESULTS
Ten patients were treated with HDC and APBSCT. Six patients achieved complete response (CR) and 1 a partial response (PR), with a response rate of 70%. Three patients did not respond following mobilization chemotherapy, and failed to respond after HDC. The median duration of progression free survival (PFS) and overall survival (OS) were 6 (4~46) and 13 (3~50+) months, respectively. The median duration of OS of the responders following mobilization chemotherapy was 23 (8~50+) compared with 12 (3~18) months of the non- responders. With regard to the treatment related toxicity, 8 patients had neutropenic fevers, and bacteremia was documented in 4. The non-hematological toxicities were never life threatening, and there were no treatment related deaths.
CONCLUSION
HDC, followed by APBSCT, is well-tolerated patients with refractory or relapsed ovarian cancer, and following mobilization chemotherapy the responders survived longer than the non-responders.

Citations

Citations to this article as recorded by

Analysis of chromosomal changes in serous ovarian carcinoma using high‐resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease
Sang Wun Kim, Jae Wook Kim, Young Tae Kim, Jae Hoon Kim, Sunghoon Kim, Bo Sung Yoon, Eun Ji Nam, Hye Yeon Kim
Genes, Chromosomes and Cancer.2007; 46(1): 1. CrossRef

4,765 View
17 Download
1 Crossref

Metastasis to the Thigh Skeletal Muscle from an Adenocarcinoma of the Duodenum: Hyo Wook Gil, Jong Ho Won, Nam Su Lee, Sang Cheol Lee, So Eun Kim, Chan Kyu Kim, Kyu Taeg Lee, Sung Kyu Park, Seung Ho Baick, Dae Sik Hong, Hee Sook Park; Cancer Res Treat. 2002;34(5):394-396. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.394

Abstract PDF: Skeletal muscle is one of the most unusual metastatic sites for any malignancy. Duodenal cancer is extremely rare, and no cases of skeletal muscle metastasis from duodenal cancer have been reported. We report here in a case of metastasis to the skeletal muscle of the left thigh from duodenal cancer. Our patient was a 47-year-old man, exhibiting a painful mass in the posterior aspect of his left thigh over a 4 month period. An imaging study, and a biopsy, revealed a duodenal adenocarcinoma metastasize to the skeletal muscle. The patient refused chemotherapy and has followed up for 4 months.

4,094 View
22 Download

A Comparison of the Acute Antiemetic Effect of Tropisetron with Ondansetron in Patients Receiving Cisplatin: Sung Tae Cho, Bo Kwon Hwang, Chan Kyu Kim, Bong Min Ko, Sung Han Bae, Jong Dae Bong, Cheol Woo Lee, Sung Kyu Park, Jong Ho Won, Seung Ho Baick, Dae Sik Hong, Hee Sook Park; J Korean Cancer Assoc. 1998;30(6):1240-1248.

Abstract PDF: PURPOSE
Tropisetron, a new specific 5-hydroxytryptamine3 (5-HT3) receptor antagonist, is an effective antiemetic agent in the control of chemotherapy induced emesis with a long half life and bioavailablity. We compared the efficacy and safefy of Tropisetron and ondansetron to control emesis induced by highly emetogenic chemotherapeutics (cisplatin > or = 50 mg/m(2)).
MATERIALS AND METHODS
Twenty-one patients were administered in a randomized, open, crossover study and received either tropisetron plus dexamethasone or ondansetron plus dexamethasone during two successive cycles of chemotherapy.
RESULTS
Control of acute emesis with either tropisetron or ondansetron was 100% vs 95.2%, and 80.9% vs 76.2% in control of delayed emesis. Both severity and duration of nausea showed no statistically significant difference between tropisetron and ondansetron. Poor appetite and headache were most common side effects in both groups.
CONCLUSION
There was no significant difference in efficacy for control of emesis and nausea between tropisetron and ondansetron in cisplatin-based chemotherapy.

2,842 View
19 Download

Comparison of Radiation Therapy and Combined Chemotherapy and Radiation Therapy for Locally Advanced Head and Neck Cancer: Gyu Taeg Lee, Jae Ho Byun, Kwon Hwangbo, Ji Oh Mok, Eun Seuk Kim, Jong Ho Won, Seung Ho Baick, Doo Ho Choi, Dae Sik Hong, Hee Sook Park; J Korean Cancer Assoc. 1997;29(4):616-622.

Abstract PDF: PURPOSE
In locally advanced head and neck cancer, radiation therapy is currently unsatisfactory because the end result is often limited regional disease control and survival. A clinical study was carried out to compare the effectiveness between the radiation therapy and the combined chemotherapy and radiation therapy.
MATERIALS AND METHOD
Thirty-six patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck were treated with radiotherapy alone and combined chemo-radiotherapy. Induction chemotherapy was administered 2~3 cycles, consisting of intravenous cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2/day for 5 days as a continuous infusion) every 4 weeks followed by 7~8 weeks of radiation therapy for a total dose of 60~75 Gy. RESULTS: 1) Among 36 locally advanced head and neck cancer, 17 patients received radiation therapy alone and 19 patients received combined chemo-radiotherapy, respectively. 2) Response rate was 47% (complete response 29%, and partial response 18%) in radiation therapy group and 79% (complete response 37%, and partial response 42%) in combined chemo-radiotherapy group (p<0.05). 3) In median survival, radiation therapy group was 13 months and combined chemo- radiotherapy group was 15 months. Both groups were not significantly different (p>0.05). 4) Treatment related mortality was not noted, but the toxic effects were seen on the half cases of the both groups. Grade II toxicities were similar between the two arms.
CONCLUSION
Combined chemotherapy and radiation therapy was more effective in local control but not superior in survival than radiation therapy alone. Continuous evaluation and identification of proper sequence for the therapeutic modality is supposed to prolong the survival of patients.

3,389 View
13 Download

A Case of Primary Splenic Angiosarcoma Associated with Kasabach-Merritt Syndrome: Jin Seok Jeon, Gyu Taek Lee, Ki Ju Han, Jae Ho Byun, Seung Kyu Park, Jong Ho Won, Seung Ho Baick, Dae Sik Hong, Hee Sook Park, Hae Kyung Lee, So Young Jin; J Korean Cancer Assoc. 1997;29(2):352-357.

Abstract PDF: PURPOSE
Primary malignant vascular neoplasms of the spleen are rare. It has been known that the prognosis was very poor and the splenectomy before rupture could increase survival. No effective chemotherapeutic protocol for angiosarcomas has yet to be established but patients with or without metastatic disease may be treated by chemotherapy. MATERIAL AND METHODS: We experienced a case of primary splenic angiosarcoma in a 42-year-old woman with multiple purpuric skin rashes associated with consumptive coagulopathy:the Kasabach-Merritt syndrome. The CT showed spleen is diffusely enlarged and inhomogenously enhanced with multiple metastasis in the liver. The splenectomy was done and angiosarcoma was diagnosed. We treated her with conventional combination chemotherapy and obtained partial response. For additional response, high-dose chemotherapy and stem cell rescue with autologous peripheral blood stem cell transplantation was done.
RESULT
Afer splenectomy, platelet count return to normal. The follow up abdominal CT scan after treatment showed complete disappeared multiple metastatic lesions in the both lobe of liver and the patient has continued to do well four months following discharge.
CONCLUSION
We herein report our experience of a splenic angiosarcoma whose multiple hepatic metastases responded well to the high-dose chemotherapy.

3,697 View
18 Download

A case of carcinoma originating from aberrant breast tissue: Tae Joon Kim, Young Hong Lee, Ki Won Kim, Jong Ho Won, Dae Sik Hong, Hee Sook Park, So Young Jin, Dong Hwa Lee, Chul Moon; J Korean Cancer Assoc. 1993;25(3):450-454.

Abstract PDF: No abstract available.

2,849 View
12 Download

A case of cardiac metastasis of hepatocelluar carcinoma through inferior vena cava: Chan Wook Park, Jin Ki Baik, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Hye Kyung Lee; J Korean Cancer Assoc. 1993;25(3):445-449.

Abstract PDF: No abstract available.

2,585 View
12 Download

The effect of chemotherapeutic agents on phagocytosis of polymorphonuclear leukocytes in patients with gastric cancer: Jong Ho Won, Dong Gib Ra, Jun Hee Woo, Dae Sik Hong, Hee Sook Park, Hi Bahl Lee; J Korean Cancer Assoc. 1992;24(2):249-255.

Abstract PDF: No abstract available.

2,123 View
13 Download

A case of malignant lymphoma developed after gastric pseudolymphoma resection: Kee Won Kim, Chang Hyun Choi, Jong Ho Won, Dae Sik Hong, Hee Sook Park, So Young Jin, Dong Wha Lee; J Korean Cancer Assoc. 1992;24(1):187-193.

Abstract PDF: No abstract available.

2,674 View
13 Download

Treatment with augmented TAD combination chemotherapy and consolidation in patient with acute myelogenous leukemia: Do Jin Kim, Jung Sil Whang, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Won Bae Kim; J Korean Cancer Assoc. 1991;23(4):798-805.

Abstract PDF: No abstract available.

2,574 View
15 Download

A clinical and electrophysiological studies of vincristine neurotoxicity: Joong Won Kim, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Yang Gyun Lee; J Korean Cancer Assoc. 1991;23(2):252-258.

Abstract PDF: No abstract available.

2,270 View
14 Download

Intracavitary Therapy with Bleomycin for The Treatment of Malignant Pleural and Pericardial Effusion: Hun Kwan Lim, Myung Lyel Lee, Jin Woo Jeon, Seong Gyu Park, Jong Ho Won, Seung Ho Baik, Dae Sik Hong, Hee Sook Park; J Korean Cancer Assoc. 1995;27(4):646-653.

Abstract PDF: Pleural effusions caused by malignancy occur commonly and are generally a manifestation of the advanced disease. Regardless of the underlying tumor type, mertality within 30 days has been reported to be as high as 50%. Respiratory insufficiency due to malignant pleural effusion often demands palliative management of the effusion. Malignant pericardial effusion is one of the most common causes of cardiac tamponade. Bleomycin and tetracycline have been widely used as sclerosing agents in malignant pleural effusion in North America and Europe. Bleomycin is less often used in the malignant pericardial effusion but is efficacious. Our study was begun to assess the effect and safety of bleomycin pleurodesis/pericardiodesis. Prospectively assigned twenty patients with malignant effusion(pleural effusion: 15, pericardial effusion; 5) to this therapy. Their age ranged from 19 to 69 years with a median of 47 years. Pri- mary sites were lung in 10, colon in 2, stomach, breast, uterine cervix, leg(sarcoma), mediastinum(malignant lymphoma), kidney in 1 each and unknown in 2(malignant melanoma and adenocarcinoma). The responses were categorized as objective response or failure. Twelve patients(70.5%) showed an objective response(complete response: 47% (8 cases), partial response: 23.5% (4 cases) out of 17 evaluable cases and the duration ranged from 5 to 78 weeks with a me- dian of 16 weeks. The response rates of malignant pericardial effusion and pleural effusion were 100/ and 61.5% respectively. Chest pain(10/17), and fever and/or chill(9/17) were the most common side effects. Other untoward effects included vomiting(4/17), anorexia(3/17), hypersensitivity(1/17), pyothorax(l/17). We conclude that bleomycin pleurodesis and pericardiodesis in malignant effusion can be performed safely and show good treatment effects, especially in maiignant pericardial effusion.

3,895 View
70 Download

High - dose Chemotherapy with Hematopoietic Stem Cell Support for Malignant Lymphoma: Young Suk Park, Jung Ae Lee, Woo Sung Min, Seonyang Park, Jing Shin Lee, Hugh Chul Kim, Hoon Kook, Jong Ho Won, Dae Sik Hong, Hee Sook Park; J Korean Cancer Assoc. 1996;28(2):316-326.

Abstract PDF: Patients with intermediate or high-grade non-Hodgkin's lymphoma(NHL) have been reported a 40% to 70% cure rate when treated with conventional chemotherapy or radiotherapy. However, most of the patients who do not attain complete remission(CR) or who relapae after chemotherapy are incurable using conventional salvage therapies and these individuals have potential for cure with high-dose therapy with reinfusion of stem cells derived from bone marrow or peripheral blood. Between February 1993 and September 1995, 26 patients with aggressive, relapsed and/or refractory malignant lymphoma were treated with high-dose chemotherapy with either autologous peripheral blood stem cell(25 patients) or bone marrow(l patient) support in 7 university hospitals in Korea. The median age was 39 years(range, l7 to 69) and male to female ratio was 4.2: 1. The common histologic types were diffuse large cell(42%), immunoblastic type(15%) of non-Hodgkin's lymphoma. The rate of complete remission was 61%(14/23) and overall remission rate was 78%(18/ 23) for the patients with measurable disease. Three patients were treated as the consolidation therapy in the status of complete remission. The median duration of remission was not reached right now. The median survival time was 7.8 months for all patients(the median follow up time; 9 months). The median time to recovery to a neutrophil count more than 0.5 x 10(9)/L was 13 days(range, 8 to 43), and to 1 x 10(9)/L was 22 days(range, 8 to 53). The median time to recovery of platelet count more than 50 x l0(9)/L and 100 x 10(9)/L were 20 days(range, 8 to 45) and 21 days(ranae, ll to 60). Non-hematologic side effects were fever, nausea and vomiting, and liver toxicity. Two toxic deaths occurred due to cardiovascular disease, mainly congestive heart failure. Based on high complete remission rate and tolerable toxicity, high-dose chemotherapy with hematopietic stem cell support appears to be a promising treatment modality for the patients with aggressive, relapsed and/or refractory malignant lymphoma.

2,816 View
14 Download

A Comparison of the Acute Antiemetic Effect of Granisetron with Combination of Metoclopramide , Dexamethasone and Lorazepam in Patients Receiving High: Won Yong Shin, Seong Gyu Park, Jin Woo Jeon, Jong Ho Won, Seung Ho Baik, Dae Sik Hong, Dae Sik Hong, Hee Sook Park; J Korean Cancer Assoc. 1996;28(3):582-589.

Abstract PDF: Granisetron, a 5-hydroxytryptamine3(5-HT3) receptor antagonist, is effective antiemetic agent in the control of cisplatin-induced emesis. We compared the efficacy and safety of granisetron with those of intravenous high-dose metoclopramide(1.5 mg/kg, four times) plus dexamethasone(10 mg i.v.) and lorazepam(2 mg i.v.)(MDL therapy) to control the acute emesis induced by high-dose cisplatin(>60mg/§³) treatment. Granisetron was injected in dose of 3 mg intravenously as recommended schedule for the prophylaxis of acute cisplatin-induced emesis. Granisetron was effective as MDL therapy for controlling of acute emesis. Of 25 granisetron-treated patients, 18(72%) were complete or major responders compared with 19/25(76%) patients who recieved the MDL therapy on first day of chemotherapy(P> 0.05). Also, in controlling of nausea, granisetron results were similar to MDL therapy. Side effects attributable to MDL group were sedation(60%)(P<0.01) and dizziness(20%)(P<0.05). In contrast to, headache(20%) of the granisetron group was higher than that of MDL group(P<0.05). Granisetron was effective as MDL therapy for controlling of the acute em esis and nausea induced by cisplatin. But, granisetron was more feasible and safer than MDL therapy.

2,807 View
15 Download

Fibrinolytic Profiles in Malignant Pleural Effusion: Seung Ho Baik, Jin Woo Jeon, Jong Ho Won, Dae Sik Hong, Hee Sook Park; J Korean Cancer Assoc. 1996;28(4):705-710.

Abstract PDF: Plasminogen activators(PAs) and their inhibitors, plasminogen activator inhibitor-l(PAI-l) are known to play an important role in tumor invasion and metastasis. The differentiation of malignant pleural effusion(PE) from non-malignant pleural effusion is important for the management of a patient. Since malignant PE is a form of metastasis, and malignant cells are considered to be able to produce PAs or PAI-1, it seems reasonable to assume that PAa and PAI-1 in PE will be in somewhat different from that in non-malignant PE. We examined urokinase- type plasminogeo activator(uPA) and uPA receptor(uPAR) and tissue-type plasminogen activator(tPA), PAI-1 antigen using ELISA method and conventional laboratory tests and adenosine deaminase(ADA) in PEs. Levels of uPA, uPAR, tPA and PAI-1 were significantly increased in malignant and tuberculous PE than transudates(p<0.05) but not statistically significant between malignant and tuberculous PE. ADA in PE showed significantly increased in tuberculous PE than malignant PE and transudate(p<0.05). These data suggests that measurement of uPA, uPAR, tPA, PAI-1 antigen in addition to ADA could be helpful to differentiate malignant PE from tuberculous PE and transudate.

2,647 View
15 Download

Search